In the international guidelines for the care of melanoma patients so far no serological tumor marker has reached an approved stage of relevance. The detection of cytokines (inter-leukin-8 and interleukin-10) in melanoma patients has demonstrated some correlation to tumor burden, but cytokines can be upregulated under several benign conditions, too. Even adhesion molecules such as ‘intercellular adhesion molecule 1’ (ICAM-1) have shown to be overexpressed in patients with a high tumor load, but several inflammatory diseases and immu-notherapeutic interventions can change serum levels as well. Thus, routine follow-up with adhesion molecule serum detection is not a useful diagnostic tool. Among the melanoma-associated antigens (MAA) detectable in serum, the Sangtec S100β protein has proved superiority compared with neuron-specific enolase (NSE) or lipid-bound sialic acid (LASA-P). Serum S100β measurements were demonstrated to serve as useful at least in the detection of advanced metastatic melanoma. Also in the monitoring of metastatic disease during the natural course of disease or during treatment, the marker proved to be of relevance. In contrast, tyrosinase reverse transcription polymerase chain reaction (RT-PCR) has failed to reach clinical significance due the low number of tyrosinase PCR-positive stage IV patients in the majority of published reports. Results of large trials with the ‘melanoma inhibitory activity’ (MIA) protein as well as optimized investigations on melanin-related metabolites (e.g. 5-S-Cysteinyl-DOPA) are awaited with great interest.